Table 1.

Study characteristics

Study	No. of study patients	No. of patientsa in meta-analysis	Duration	Agec	Per cent women	Study treatment	Antiplatelet drugs		Bleeding events used in the present study
							Single (%)	Dual (%)
ESTEEM11	1900	1883	6 months	68	32	Ximelagatran 24, 36, 48, or 60 mg b.i.d., or placebo	100	–	ISTH major and clinically relevant non-major bleeds
APPRAISE-112	1715	1210b	6 months	61	24	Apixaban 2.5 mg b.i.d., 10 mg o.d., or placebo	24	76	ISTH major and clinically relevant non-major bleeds
ATLAS ACS-TIMI4613	3462	1997b	6 months	57	23	Rivaroxaban 5 mg o.d., 5 mg b.i.d., 10 mg o.d., or placebo	25	75	TIMI clinically significant bleeding (TIMI major bleeding, TIMI minor bleeding, or bleeding requiring medical attention)
REDEEM14	1878	1861	6 months	62	24	Dabigatran 50, 75, 110. or 150 mg b.i.d. or placebo	2	98	ISTH major and clinically relevant non-major bleeds
RUBY-115	1279	1258	6 months	57	20	Darexaban 5, 15 or 30 mg b.i.d., 10, 30 or 60 mg o.d., or placebo	5	95	ISTH major and clinically relevant non-major bleeds
APPRAISE-216	7392	7315	8 months	67	32	Apixaban 5 mg (or 2.5 mgd) b.i.d., or placebo	19	81	TIMI major bleeds; ISTH major and clinically relevant non-major bleeds
ATLAS ACS2-TIMI5117	15 526	15 342	13 months	62	25	Rivaroxaban 2.5 or 5 mg b.i.d., or placebo	7	93	TIMI major (non-CABG related) bleeds, TIMI bleeding requiring medical attention

o.d., once daily; b.i.d., twice daily; ISTH, International Society on Thrombosis and Haemostasis; TIMI, Thrombolysis in Myocardial Infarction.

See Methods for description of inclusion and exclusion criteria. Single antiplatelet therapy includes patients not receiving any antiplatelet medication at randomization, dual antiplatelet treatment consists of aspirin and clopidogrel at randomization.

^aNo. of patients who received at least one dose of study drug.

^bNo. of patients treated with daily doses also evaluated in phase III study.

^cMean or median.

^dApixaban 2.5 mg b.i.d. in 8.5% of the patients with estimated creatinine clearance <40 mL/min.